Novo Nordisk, Lilly see insatiable demand for weight-loss drugs reuters.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from reuters.com Daily Mail and Mail on Sunday newspapers.
By Maggie Fick and Bhanvi Satija (Reuters) - Novo Nordisk and Eli Lilly both expect juggernaut sales for their diabetes and weight-loss drugs to exten.
Irish doctors have raised concerns about the delayed launch of a “game-changing” drug to treat obesity in Ireland after overwhelming demand for the product in
Operator: Good day, and thank you for standing by. Welcome to the First Quarter 2023 Novo Nordisk A/S Earnings Conference Call. . Please be advised that this conference is being recorded.